Samuel D Banister Selected Research

Samuel D Banister Research Topics

Disease

7	Hypothermia 01/2022 - 08/2015
6	Epilepsy (Aura) 01/2023 - 01/2021
5	Seizures (Absence Seizure) 01/2023 - 11/2019
4	Pica (Geophagia) 01/2023 - 10/2017
4	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2023 - 11/2019
3	Neuralgia (Stump Neuralgia) 11/2019 - 10/2016
3	Bradycardia 10/2017 - 09/2015
3	Schizophrenia (Dementia Praecox) 01/2016 - 05/2015
2	Neuroinflammatory Diseases 04/2020 - 01/2013
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 05/2015
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 03/2018
2	Multiple Sclerosis 11/2019 - 01/2019
2	Central Nervous System Diseases (CNS Diseases) 01/2016 - 03/2013
1	Pain (Aches) 01/2022
1	Respiratory Acidosis 01/2020
1	Obesity 11/2019
1	Tourette Syndrome (Tourette's Syndrome) 01/2019
1	Anorexia Nervosa 01/2019
1	Vomiting 01/2019
1	Nausea 01/2019
1	Chronic Pain 01/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 03/2018
1	Weight Gain 01/2017
1	Neoplasms (Cancer) 01/2017
1	Memory Disorders (Memory Loss) 01/2017
1	Glioblastoma (Glioblastoma Multiforme) 01/2017
1	Nervous System Diseases (Neurological Disorders) 10/2016
1	Glioma (Gliomas) 03/2015
1	Brain Diseases (Brain Disorder) 01/2013
1	Brain Ischemia (Cerebral Ischemia) 01/2013

Drug/Important Bio-Agent (IBA)

7	CannabinoidsIBA 01/2023 - 01/2017
4	Anticonvulsants (Antiepileptic Drugs)IBA 01/2023 - 11/2019
4	Proteins (Proteins, Gene)FDA Link 04/2020 - 01/2013
3	T-Type Calcium Channels (T-Type Calcium Channel)IBA 01/2023 - 01/2022
3	cumyl-PINACAIBA 01/2023 - 10/2017
3	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 11/2019
3	LigandsIBA 01/2017 - 01/2013
3	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2016 - 05/2015
2	CannabidiolIBA 01/2023 - 06/2022
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2022 - 05/2019
2	N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA 01/2017 - 01/2013
2	AB-FUBINACAIBA 01/2017 - 09/2015
2	N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- pentyl- 1H- indazole- 3- carboxamideIBA 01/2017 - 09/2015
1	Cumyl-CBMICAIBA 01/2023
1	SodiumIBA 06/2022
1	Terpenes (Terpenoids)IBA 06/2022
1	cannabigerolic acidIBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	olivetolic acidIBA 01/2022
1	EstersIBA 01/2022
1	Illicit Drugs (Recreational Drugs)IBA 01/2022
1	cannabichromeneIBA 01/2021
1	OilsIBA 01/2021
1	5F-CUMYL-PICAIBA 11/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	AcidsIBA 11/2019
1	cannabidiolic acidIBA 11/2019
1	5F-CUMYL-P7AICAIBA 02/2019
1	ZLN005IBA 03/2018
1	pyrimidineIBA 01/2017
1	Ether (Diethyl Ether)IBA 01/2017
1	Dronabinol (THC)FDA LinkGeneric 01/2017
1	acetamideIBA 01/2017
1	N,N- diethyl- 2- (2- (4- methoxyphenyl)- 5,7- dimethyl- pyrazolo(1,5- a)pyrimidin- 3- yl)- acetamideIBA 01/2017
1	Sigma-1 ReceptorIBA 10/2016
1	methyl (1- (5- fluoropentyl)- 1H- indazole- 3- carbonyl)valinateIBA 01/2016
1	1-pentyl-3-(1-naphthoyl)indoleIBA 08/2015
1	PregnenoloneIBA 03/2015
1	PK 11195 (PK11195)IBA 01/2013
1	(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamideIBA 01/2013

Therapy/Procedure

3	Induced Hyperthermia (Thermotherapy) 01/2023 - 01/2021
2	Therapeutics 05/2019 - 01/2017
2	Induced Hypothermia 10/2017 - 09/2015
1	Drug Therapy (Chemotherapy) 01/2019